FY2025 Supplementary Material of Financial Results

Consolidated Financial Results for the Year Ended March 31, 2026(Based on Japanese GAAP)

Notice of Recognition of an Impairment Loss, Recognition of a Loss on Valuation of Shares of Subsidiaries and Associates in the Non-consolidated Financial Statements of the Company, and Revisions of Financial Forecasts

Toward Ensuring a Stable Supply of Off-Patent Medical Products Towa Pharmaceutical Agrees to Collaborate with Sanwa Kagaku Kenkyusho Co., Ltd., with the Aim of Establishing a Backup Production System

Toward Ensuring a Stable Supply of Off-Patent Medical Products*1 Towa Pharmaceutical Concludes a Basic Agreement with Adragos Pharma Kawagoe on a Contract Manufacturing Partnership for Pharmaceuticals